Drug patents in Africa: exactly how long they last—and why it matters more than ever
If you’ve ever wondered why some medicines seem to arrive late, cost more than expected, or remain out of reach for years, the answer is often hiding in plain sight: p…

🚦 Green light to launch: the definitive step-by-step FTO analysis guide is here—and it could change how new drug products get to market.
In pharma, the hardest part isn’t always the science. It’s the risk math—the moment you ask: Can we launch witho…

Biotech investors don’t lose money because they can’t read the science. They lose money because they overpay for the wrong signals.
Here’s the uncomfortable truth: most “value” frameworks in biotech are built on narratives—platform potential, pipeline …

Generic and biosimilar timing isn’t a guess—it’s a discipline.
If you’re managing formularies, contracts, or patient access, you’ve probably felt the pressure: a brand’s “exclusivity” is expiring, competitors are circling, and internal stakeholders w…

Before a drug ever hits a press release, the real competition is already in motion.
Most teams only react once a pipeline is public—when a company files a press release, posts trial results, or publishes a slide deck. But in pharma, “public” is often…

20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is a simple countdown: 20 years from filing. In reality, the clock is more like a relay race—multiple “start times,” multiple legal events…

Pick the Right Patent—or Leave Billions on the Table: The One-Patent-Per-Product Rule and PTE Selection Strategy
In pharma, the difference between winning and losing isn’t always the science. Often, it’s the paperwork—specifically, which patent you cho…